Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma
- 1Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030000, China
- 2Fifth Tianjin Central Hospital, Tianjin 300450, China
Abstract
Objective: To investigate the clinical characteristics and prognostic significance of distinct Ki-67 proliferation indices in patients with newly diagnosed multiple myeloma (NDMM). Methods: A retrospective analysis of clinical data from 307 NDMM patients admitted to the Second Hospital of Shanxi Medical University from January 2015 to December 2023. Patients were stratified into two cohorts based on Ki-67 proliferation index: Ki-67 > 10% and Ki-67 ≤ 10%. Results: Among the 307 enrolled NDMM patients, 199 (64.82%, 199/307) were assigned to the Ki-67 ≤ 10% group. The median progression-free survival (mPFS) was 45.52 months (95% CI: 39.40–51.66) in the Ki-67 ≤ 10% group, compared with 25.81 months (95% CI: 20.61–31.00) in the Ki-67 > 10% group, with a statistically significant difference in PFS between the two cohorts (p < 0.001). Between these two groups, the median Overall Survival (mOS) reached 61.61 months (95% CI: 54.48–68.74) in the Ki-67 ≤ 10% group and 34.78 months (95% CI: 28.89–40.66) in the Ki-67 > 10% group, with a statistically significant difference in OS between the two cohorts (p < 0.001). Multivariate Cox proportional hazards regression analysis demonstrated that the Ki-67 proliferation index served as an independent prognostic factor for both PFS (HR:1.227; 95% CI: 1.097–1.743; p = 0.043) and OS (HR:1.192; 95% CI: 1.169–1.847; p = 0.048) in patients with NDMM. Subsequently, patients with NDMM were stratified into three risk groups based on the combination of International Staging System (ISS) stage and Ki-67 proliferation index. A total of 103 patients (33.55%) were classified into group I, 138 patients (44.95%) into group II, and 66 patients (21.50%) into group III. Survival analyses revealed significant differences in survival outcomes across the three combined staging groups. The mPFS was 49.74 months (95% CI: 28.81–63.19) in group I, 35.00 months (95% CI: 24.82–45.18) in group II, and 17.00 months (95% CI: 13.94–20.06) in group III patients, with a statistically significant inter-group difference in PFS (p = 0.011). Meanwhile, the mOS of the three groups was 71.38 months (95% CI: 63.59–79.17), 59.51 months (95% CI: 51.74–67.28), and 26.64 months (95% CI: 22.31–30.98), respectively. There was an obvious significant difference in OS among the three groups (p < 0.001). Conclusions: NDMM patients with Ki-67 proliferation index > 10% have a significantly worse prognosis than those with Ki-67 ≤ 10%. A high Ki-67 index (>10%) is identified as an independent adverse prognostic parameter for NDMM. Furthermore, the integration of Ki-67 proliferation index with ISS staging can substantially enhance the accuracy of prognostic risk stratification in patients with NDMM.
Related
- Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma
- Lymph Node Regression Improves Prognostic Stratification in Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Cohort Study.
- A Histology‐Derived Score Integrating Tumor–Stroma Ratio, Tertiary Lymphoid Structures, and Tumor Budding Improves Prognostic Stratification in Colorectal Cancer
- Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
- Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
BibTeX
@article{qin2026ki67,
title = {{Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma}},
author = {Xiaoqi Qin and Jingliang Zhao and Qirui Bai and Qile Qiu and Shengtao Li and Yifan Zhang and Lin Zhang and Yanping Ma},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203312},
url = {https://www.mdpi.com/2072-6694/18/20/3312},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ki-67 Proliferation Index Improves the Prognostic Stratification Accuracy of International Staging System in Newly Diagnosed Multiple Myeloma
AU - Xiaoqi Qin
AU - Jingliang Zhao
AU - Qirui Bai
AU - Qile Qiu
AU - Shengtao Li
AU - Yifan Zhang
AU - Lin Zhang
AU - Yanping Ma
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203312
UR - https://www.mdpi.com/2072-6694/18/20/3312
AB - Objective: To investigate the clinical characteristics and prognostic significance of distinct Ki-67 proliferation indices in patients with newly diagnosed multiple myeloma (NDMM). Methods: A retrospective analysis of clinical data from 307 NDMM patients admitted to the Second Hospital of Shanxi Medical University from January 2015 to December 2023. Patients were stratified into two cohorts based on Ki-67 proliferation index: Ki-67 > 10% and Ki-67 ≤ 10%. Results: Among the 307 enrolled NDMM patients, 199 (64.82%, 199/307) were assigned to the Ki-67 ≤ 10% group. The median progression-free survival (mPFS) was 45.52 months (95% CI: 39.40–51.66) in the Ki-67 ≤ 10% group, compared with 25.81 months (95% CI: 20.61–31.00) in the Ki-67 > 10% group, with a statistically significant difference in PFS between the two cohorts (p < 0.001). Between these two groups, the median Overall Survival (mOS) reached 61.61 months (95% CI: 54.48–68.74) in the Ki-67 ≤ 10% group and 34.78 months (95% CI: 28.89–40.66) in the Ki-67 > 10% group, with a statistically significant difference in OS between the two cohorts (p < 0.001). Multivariate Cox proportional hazards regression analysis demonstrated that the Ki-67 proliferation index served as an independent prognostic factor for both PFS (HR:1.227; 95% CI: 1.097–1.743; p = 0.043) and OS (HR:1.192; 95% CI: 1.169–1.847; p = 0.048) in patients with NDMM. Subsequently, patients with NDMM were stratified into three risk groups based on the combination of International Staging System (ISS) stage and Ki-67 proliferation index. A total of 103 patients (33.55%) were classified into group I, 138 patients (44.95%) into group II, and 66 patients (21.50%) into group III. Survival analyses revealed significant differences in survival outcomes across the three combined staging groups. The mPFS was 49.74 months (95% CI: 28.81–63.19) in group I, 35.00 months (95% CI: 24.82–45.18) in group II, and 17.00 months (95% CI: 13.94–20.06) in group III patients, with a statistically significant inter-group difference in PFS (p = 0.011). Meanwhile, the mOS of the three groups was 71.38 months (95% CI: 63.59–79.17), 59.51 months (95% CI: 51.74–67.28), and 26.64 months (95% CI: 22.31–30.98), respectively. There was an obvious significant difference in OS among the three groups (p < 0.001). Conclusions: NDMM patients with Ki-67 proliferation index > 10% have a significantly worse prognosis than those with Ki-67 ≤ 10%. A high Ki-67 index (>10%) is identified as an independent adverse prognostic parameter for NDMM. Furthermore, the integration of Ki-67 proliferation index with ISS staging can substantially enhance the accuracy of prognostic risk stratification in patients with NDMM.
SN - 2072-6694
ER -